**Supplementary Table S3**: Prevalence of hr-HPV types among all 85 CIN2+ cases, stratified by age

|  |  |  |  |
| --- | --- | --- | --- |
| **hr-HPV Type** | **All CIN2+**†**N=85** | **CIN2+ <30 years****n=21** | **CIN2+ ≥30 years****n=64** |
|   | **Self** | **Provider** | **Self** | **Provider** | **Self** | **Provider** |
| **All hr-HPV\*** | 79 (93%) | 80 (94%) | 21 (100%) | 21 (100%) | 58 (91%) | 59 (92%) |
| **16** | 39 (46%) | 34 (40%) | 13 (62%) | 10 (48%) | 26 (41%) | 24 (38%) |
| **18** | 7 (8%) | 6 (7%) | 0 (0%) | 1 (5%) | 7 (11%) | 5 (8%) |
| **31** | 9 (11%) | 8 (9%) | 3 (14%) | 2 (10%) | 6 (9%) | 6 (9%) |
| **45** | 6 (7%) | 5 (6%) | 1 (5%) | 1 (5%) | 5 (8%) | 4 (6%) |
| **33/58** | 10 (12%) | 9 (11%) | 2 (10%) | 2 (10%) | 8 (13%) | 7 (11%) |
| **35/39/68** | 13 (15%) | 14 (17%) | 5 (24%) | 5 (24%) | 8 (13%) | 9 (14%) |
| **51** | 8 (9%) | 8 (9%) | 3 (14%) | 3 (14%) | 5 (8%) | 5 (8%) |
| **52** | 13 (15%) | 13 (15%) | 2 (10%) | 2 (10%) | 11 (17%) | 11 (17%) |
| **56/59/66** | 17 (20%) | 17 (20%) | 7 (33%) | 7 (33%) | 10 (16%) | 10 (16%) |

\*hr-HPV: Any of the 14 high-risk HPV types detected by the Onclarity assay

†CIN2+: Cervical intraepithelial neoplasia grade 2 or higher